Clinical Rationale for Targeting CEACAM5

CEACAM5 is a member of the CEACAM family of glycoproteins. It is a cell adhesion molecule that1:

  • in normal and tumor tissues, connects adjacent cell membranes1
  • when overexpressed, inhibits differentiation and apoptosis2-4
  • when overexpressed, disrupts cell polarization and tissue architecture3
  • inhibits natural killer cytotoxicity by interacting with natural killer inhibitory receptor CEACAM11
  • as a soluble form, CEACAM5 induces pro-inflammatory cytokines that increase binding of circulating tumor cells to the endothelium1

When levels are elevated, CEACAM5 may contribute to tumor development and metastasis through several mechanisms.1

The discovery of CEA and the CEACAM family1

CEACAM5, formerly known as CEA (carcinoembryonic antigen), was first discovered as a tumor-associated antigen for colorectal carcinoma.

This discovery led to the further identification of other CEA-related proteins, later unified under the name CEACAM family.

12 glycoproteins of the human CEACAM family1,5

12 glycoproteins of the human CEACAM family.
  • IgV-like domains
  • IgC2-like domains stabilized by disulfide bonds
  • transmembrane helices
  • ending in the lipid bilayer (GPI anchors)
  • Adapted from Beauchemin et al. Cancer Metastasis Rev. 2013;32(3-4):643-6711; Hammarström. Semin Cancer Biol. 1999;9(2):67-81.5

Watch Prof Thomas talk about how CEACAM5 can affect tumor development

Learn more about CEACAM5
and the CEACAM family